Gilead reports early results of partnership with Beth Israel for HIV therapy

California-based biotech Gilead yesterday reported the results from a pre-clinical study conducted in partnership with Beth Israel Deaconess Medical Center, aimed at assessing the TLR7 (Receptor 7 agonist)-PGT121 combination for the treatment of HIV. The test has been conducted on a sample of macaco rhesus monkeys. 45% of the animals treated with GS-9620 and PGT121 has positively reacted to the treatment, which has demonstrated efficacy in completely eradicating HIV. The research was funded partly by the Bill & Melinda Gates Foundation and partly by the National Institute of Allergy and Infectious Diseases.

(Source: Gilead)